However, the effectiveness of early-stage treatment with chemotherapeutic agents targeting wild-type epidermal growth factor receptor (EGFR) in NSCLC remains uncertain, as previous research has suggested limited benefits for patient survival [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.